{"nct_id":"NCT02263508","title":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","status":"TERMINATED","status_verified_date":"2022-11","start_date":"2014-12-08","start_date_type":"ACTUAL","primary_completion_date":"2021-03-11","primary_completion_date_type":"ACTUAL","completion_date":"2021-03-11","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["AMGN"]}